

# PURPOSE

A summary of **PURPOSE 2**, a study looking at how well lenacapavir works for HIV prevention in cisgender gay, bisexual, and other men, transgender people, and gender nonbinary people who have sex with partners assigned male at birth

**Onyema Ogbuagu\*** on behalf of the **PURPOSE 2 Study Team**

Section of Infectious Diseases and Department of Pharmacology, Yale School of Medicine, New Haven, Connecticut, USA

This is a summary of a scientific presentation that was originally presented by Dr Onyema Ogbuagu at HIV Glasgow 2024 (Twice-Yearly Lenacapavir PrEP in Cisgender Gay, Bisexual and Other Men, Transgender Women and Men, and Gender-Diverse People [PURPOSE 2]). This summary only presents selected data and is not intended to replace the full presentation. The intended audience for this summary is registered conference attendees.

\*For a list of co-authors, please see the original presentation

See [www.purposestudies.com](http://www.purposestudies.com) for more information on the PURPOSE studies

## Background

Taking PrEP (pre-exposure prophylaxis) medications can reduce the chances of a person getting HIV.

Standard-of-care oral PrEP is a once-daily emtricitabine and tenofovir disoproxil fumarate (F/TDF) tablet. However, some people are unable to take F/TDF as prescribed, which can make the medication less effective. New PrEP options are needed, particularly for people who are disproportionately affected by HIV, including people of color and gender-diverse people.

Lenacapavir is an investigational medication for HIV prevention that works by targeting the capsid protein, which is needed for the HIV virus to replicate. Lenacapavir is given as an injection under the skin every 6 months.

**In the PURPOSE 2 study, researchers looked at cisgender gay, bisexual, and other men, transgender people, and gender nonbinary individuals who have sex with partners assigned male at birth and who received lenacapavir, to see how well it worked at preventing HIV. They also looked at how well lenacapavir worked compared with F/TDF.**

## Why did researchers do this analysis?

Researchers wanted to know how well lenacapavir works to prevent HIV in cisgender gay, bisexual, and other men, transgender women, transgender men, and gender nonbinary individuals who have sex with male partners.

## Who took part in the study and how were the medications studied?

**4634** people were tested for HIV at the start of the study. The results of this testing were used to calculate [the background HIV rate](#).



Because effective PrEP options exist, a true placebo group (with no active drug) was not used in this innovative study design. Researchers compared medications against the “background HIV rate,” which was calculated by testing people for HIV at a screening visit. Positive samples were tested with a recency test, which determined if people had acquired HIV recently. Researchers then used that information to calculate the expected rate of new HIV infections in people not on PrEP

**3271** people tested negative for HIV and received one of the study drugs (lenacapavir or F/TDF). Neither the doctors nor the study participants knew which group participants were assigned to. **Six** people were diagnosed with HIV on Day 1 of the study and therefore were not included in the analyses.

People randomized in the study



At least 16 years of age




67% non-White



22% identified as gender diverse

- 15% transgender women
- 6% gender nonbinary
- 1% transgender men

Study design



If diagnosed with HIV, people were referred to HIV care to start treatment for HIV. The samples were tested with a recency test to calculate the background HIV rate.

What was measured?

Researchers measured the **incidence of HIV in each study group** and the background HIV incidence as the number of new HIV infections per “person-year.” A person-year is equal to one person studied for 1 year. Researchers measured how many people had **injections on time** or **took the number of tablets as directed**. Researchers also looked at **whether the drugs were safe**, including assessment of injection-site reactions.



**PURPOSE 2** enrolled the most diverse population of people of different races, ethnicities, and genders, across a broad age range, including people aged 17 to 74 years

# A summary of PURPOSE 2, a study looking at how well lenacapavir works for HIV prevention in cisgender gay, bisexual, and other men, transgender people, and gender-nonbinary people who have sex with partners assigned male at birth

## What were the results?

Over 99.9% of participants who took lenacapavir did not acquire HIV

Lenacapavir reduced the risk of acquiring HIV by:



2 out of 2179 people taking lenacapavir got HIV

→ 0.10 cases per 100 person-years

9 out of 1086 people taking F/TDF got HIV


→ 0.93 cases per 100 person-years

The background HIV rate in 4634 people was


→ 2.37 cases per 100 person-years

- Both people taking lenacapavir who got HIV had an N74D capsid resistance mutation.
- There was no evidence that lenacapavir delayed HIV diagnosis by standard HIV serologic testing in these two people.

## Did people adhere to lenacapavir and F/TDF at 12 months?



of people received on-time lenacapavir injection (< 28 weeks from last injection)



of people in the F/TDF group were taking four or more tablets per week (high adherence)

The nine people in the F/TDF group who got HIV had either stopped taking F/TDF or were taking fewer than two tablets per week (low adherence)

## How safe was 12 months of lenacapavir or F/TDF medication?

Lenacapavir and F/TDF were safe and well tolerated

- Lenacapavir and F/TDF were well tolerated by the people in the study, and only seven people in each group stopped receiving the medications because of side effects other than injection-site reactions.
- Aside from injection-site reactions, the most common side effects experienced by at least 10% of people during the study were rectal chlamydia infection, oropharyngeal gonococcal infection, and rectal gonococcal infection.



Lenacapavir is injected under the skin into the space between skin and muscle where it forms a collection of drug, called a drug depot. Sometimes people can feel the depot through their skin, but usually it is not visible



The most common side effects reported during the study were injection-site reactions, including pain, redness, or a lump under the skin at the site of the injection.

Among 10,094 lenacapavir and 5145 placebo injections administered during the study, only 26 and three people, respectively, discontinued due to injection-site reactions.

Over time, as people received more injections, they experienced fewer injection-site reactions.

## Conclusions

- Lenacapavir reduced the risk of acquiring HIV by 96% vs the background HIV rate and was 89% better than F/TDF
- Most people received injections on time; F/TDF adherence was high but declined over time
- There was no delay in HIV diagnosis using standard HIV testing in people taking lenacapavir who acquired HIV
- Lenacapavir and F/TDF were safe and well tolerated
- All of the people who participated in the study are now being offered lenacapavir
- Twice-yearly lenacapavir was highly efficacious for HIV prevention among the most globally, racially, and ethnically diverse population of 17- to 74-year-old cisgender gay, bisexual, and other men; transgender women; transgender men; and gender nonbinary people

ACCESS: Please see the full access statements:

<https://www.gilead.com/company/company-statements/2024/updated-statement-on-access-planning-in-high-incidence-resource-limited-countries-for-lenacapavir-for-hiv-prevention> (accessed November 5, 2024).

<https://www.gilead.com/news/news-details/2024/gilead-signs-royalty-free-voluntary-licensing-agreements-with-six-generic-manufacturers-to-increase-access-to-lenacapavir-for-hiv-prevention-in-high-incidence-resource-limited-countries> (accessed November 5, 2024).

Gilead believes working directly with generic manufacturers (voluntary licensing) is the fastest way to create broad and sustainable access to lenacapavir for PrEP for people who need it the most.

Reference: Ogbuagu O, et al. Oral O49 presented at: HIV Glasgow; November 10-13, 2024; Glasgow, UK.

Acknowledgments: Thank you to the trial participants, their families and communities, the investigators and site staff, the members of the PURPOSE 2 study team, and the Global Community Advisory Group. This study was funded by Gilead Sciences, Inc. Medical writing support was provided by Heather Davies, PhD, Aspire Scientific Ltd (Bollington, UK) and was funded by Gilead Sciences, Inc.

See [www.purposestudies.com](http://www.purposestudies.com) for more information